Research progress of non-small cell lung cancer with epidermal growth factor receptor mutation subtype and immune checkpoint blocking treatment
WU Liu-sheng1,2,3 LI Xiao-qiang1,3▲
1. Peking University Shenzhen Hospital, Clinical College of Anhui Medical University
2.Department of Graduate School,Anhui Medical University
3. Department of Thoracic Surgery, Peking University Shenzhen Hospital
Abstract：Lung cancer is a tumor-related disease with the highest incidence and mortality in the world. Non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancer incidence rates and it has become the most concerned pathology type in the medical community. The International Association for the Study of Lung Cancer,American Thoracic Society and the European Respiratory Society (IASLC/ATS/ERS) first proposed the inextricable relationship between the pathological type of NSCLC and the mutant subtype of epidermal growth factor receptor (EGFR).NSCLC patients with different subtypes of EGFR mutations are sensitive to tyrosine kinase inhibitors (TKIs) that exist when receiving the same EGFR-TKI treatment, and the ideal therapeutic effect can be achieved in the early stage, but subsequent resistance often occurs, which makes treatment difficult. Due to the difference in efficacy, these patients also have occurred drug resistance after receiving the first-generation or second-generation EGFR-TKI. Even the use of Osimertinib (the third-generation EGFR-TKI) still cannot greatly meet the clinical treatment needs. Therefore,immune checkpoint inhibitors (ICIs) have become a treatment options that researchers are competing to explore. This article aims to provide a comprehensive overview for the research progress of EGFR mutation subtypes and immune checkpoint blocking treatment in advanced NSCLC.
Hastings K，Yu HA，Wei W，et al.EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer[J].Ann Oncol，2019，30（8）：1311-1320.
[9]
Lee HT，Lee SH，Heo YS.Molecular Interactions of Antibody Drugs Targeting PD-1，PD-L1 and CTLA-4 in Immuno-Oncology[J].Molecules，2019，24（6）：1190.
[10]
Remon J，Steuer CE，Ramalingam SS，et al.Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients[J].Ann Oncol，2018，29（suppl_1）：i20-i27.
[11]
Tan CS，Kumarakulasinghe NB，Huang YQ，et al.Third generation EGFR TKIs：current data and future directions[J].Mol Cancer，2018，17（1）：29.
[12]
Su S，Dong ZY，Xie Z，et al.Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation[J].J Thorac Oncol，2018，13（11）：1668-1675.
[13]
Del Re M，Crucitta S，Gianfilippo G，et al.Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC：From Tissue to Liquid Biopsy to Guide Treatment Strategy[J].Int J Mol Sci，2019，20（16）：3951.
[15]
Roskoski R Jr.Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers[J].Pharmacol Res，2019，139：395-411.
[17]
Wang Z.ErbB Receptors and Cancer[J].Methods Mol Biol，2017，1652：3-35.
[20]
Ghosh A，Yan H.Hydrogen bond analysis of the EGFRErbB3 heterodimer related to non-small cell lung cancer and drug resistance[J].J Theor Biol，2019，464：63-71.
[24]
Wang Z，Candelora.In Vitro Enzyme Kinetics Analysis of EGFR[J].Methods Mol Biol，2017，1487：23-33.
[14]
Kobayashi K，Seike M，Zou F，et al.Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression[J].Anticancer Res，2018，38（2）：753-762.
[16]
Goyal S，Jamal S，Shanker A，Grover A.Structural Basis for Drug Resistance Mechanisms Against EGFR[J].Curr Top Med Chem，2017，17（22）：2509-2521.
Dokala A，Thakur SS.Extracellular region of epidermal growth factor receptor：a potential target for anti-EGFR drug discovery[J].Oncogene，2017，36（17）：2337-2344.
[25]
Bello M.Binding mechanism of kinase inhibitors to EGFR and T790M，L858R and L858R/T790M mutants through structural and energetic analysis[J].Int J Biol Macromol，2018，118（Pt B）：1948-1962.
[26]
Suresh K，Naidoo J，Lin CT，et al.Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer：Benefits and Pulmonary Toxicities[J].Chest，2018，154（6）：1416-1423.
[27]
Sears CR，Peikert T，Possick JD，et al.Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis.An Official American Thoracic Society Research Statement[J].Am J Respir Crit Care Med，2019，200（6）：e31-e43.
[28]
Cho JY，Kim J，Lee JS，et al.Characteristics，incidence，and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer[J].Lung Cancer，2018，125：150-156.
京公网安备 11010502046607号